Eli Lilly and Company, Merck KGaA Erbitux Fails to Stop Colon Cancer Before It Spreads

Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage.